Treatment of Benign Prostatic Hyperplasia (BPH)
BPH is non-malignant enlargement of the prostate gland causing lower urinary tract symptoms including weak stream, frequency, urgency, and nocturia. It is nearly universal in men over 80; alpha-blockers and 5-alpha reductase inhibitors are first-line treatments.
Managing Benign Prostatic Hyperplasia (BPH) effectively requires a combination of medical treatment, lifestyle modification, and regular monitoring. With a structured management plan, most people with Benign Prostatic Hyperplasia (BPH) can maintain a good quality of life and prevent serious complications.
First-Line Treatment Principles
- ✓BP control: target <130/80 mmHg; ACE inhibitor or ARB for proteinuric CKD
- ✓SGLT2 inhibitors for CKD with proteinuria (regardless of diabetes): reduce CKD progression by 30–40%
- ✓Treat underlying cause: immunosuppression for glomerulonephritis, antiviral for viral-associated nephropathy
- ✓Fluid management: adequate hydration in AKI; fluid restriction in oliguric/ESRD patients
- ✓Treat complications: anaemia (EPO/iron), bone disease (phosphate binders, vitamin D), hyperkalaemia
What to Do Now
- Learn your personal risk factors for Benign Prostatic Hyperplasia (BPH) (family history, age, lifestyle)
- Attend regular health check-ups and screening tests appropriate for your age and risk
- Track new or changing symptoms, especially those associated with Benign Prostatic Hyperplasia (BPH)
- Use our AI symptom checker to assess whether your symptoms fit an early Benign Prostatic Hyperplasia (BPH) pattern
- Discuss preventive strategies and early monitoring with your GP
- Build a personalised management plan with your GP or specialist
- Adhere consistently to prescribed medications — do not stop without medical advice
- Adopt a Benign Prostatic Hyperplasia (BPH)-appropriate diet (anti-inflammatory, low-glycaemic, or disease-specific)
Medications Used in Benign Prostatic Hyperplasia (BPH)
Doxazosin is an alpha-1 blocker used to treat hypertension and benign prostatic hyperplasia by relaxing smooth muscle in blood vessels and the prostate.
Prazosin is an alpha-1 blocker used to treat hypertension and benign prostatic hyperplasia by relaxing smooth muscle in blood vessels and the prostate.
Terazosin is an alpha-1 blocker used to treat hypertension and benign prostatic hyperplasia by relaxing smooth muscle in blood vessels and the prostate.
Tamsulosin is an alpha-1 blocker that relaxes smooth muscle in the prostate and bladder neck to improve urinary flow in benign prostatic hyperplasia.
Alfuzosin is an alpha-1 blocker that relaxes smooth muscle in the prostate and bladder neck to improve urinary flow in benign prostatic hyperplasia.
Finasteride is a 5-alpha reductase inhibitor that shrinks the prostate in BPH and reduces hair loss in androgenic alopecia.
Dutasteride is a 5-alpha reductase inhibitor that shrinks the prostate in BPH and reduces hair loss in androgenic alopecia.
Non-Pharmacological Management
- •Dietary protein restriction (0.6–0.8 g/kg/day) in advanced CKD to slow progression
- •Sodium restriction (<2g/day) for BP and fluid management
- •Potassium restriction in hyperkalaemia; phosphate restriction in ESRD
- •Fluid management: adequate intake in early CKD; restrict to 1.0–1.5L/day in oliguric ESRD
- •Smoking cessation: accelerates CKD progression
- •Weight management: obesity drives glomerular hyperfiltration and proteinuria
- •Regular aerobic exercise where tolerated; renal rehabilitation programmes
Treatment Goals
Monitoring Parameters
- ◆eGFR and creatinine: 3–6 monthly in CKD stages 3–4; monthly in CKD stage 5 or rapid progressors
- ◆Urine albumin-creatinine ratio (UACR): every 3–6 months
- ◆Electrolytes: potassium (ACE inhibitor/ARB risk), sodium, bicarbonate, phosphate — 3–6 monthly
- ◆FBC: haemoglobin target 100–120 g/L with EPO therapy
- ◆Parathyroid hormone (PTH), calcium, phosphate: for renal bone disease monitoring
- ◆BP: target at every visit
Red Flags — When to Escalate
- ⚠Any of the characteristic symptoms of Benign Prostatic Hyperplasia (BPH) — even mild — in a high-risk individual
- ⚠Progressive worsening of early warning signs over weeks
- ⚠Laboratory abnormalities (e.g., blood sugar, inflammatory markers) without full symptoms
- ⚠Unexplained weight loss, night sweats, or fatigue persisting >2 weeks
- ⚠Strong family history of Benign Prostatic Hyperplasia (BPH) combined with new relevant symptoms
- ⚠Sudden worsening of Benign Prostatic Hyperplasia (BPH) symptoms despite established treatment
Escalation Criteria
- →AKI: urgent assessment for reversible causes; IV fluids if pre-renal; emergency dialysis if urea >35, K+>6.5, acidosis, or fluid overload
- →Rapidly progressive GFR decline → renal biopsy and specialist nephrology review
- →Hyperkalaemia >6.5 mmol/L: immediate cardiac monitoring, calcium gluconate IV, insulin-dextrose, dialysis if refractory
- →Prepare for renal replacement therapy (RRT) education when eGFR <20: home dialysis or transplant listing
Special Populations
Clinical Insights
Compare With Similar Conditions
Not sure about your symptoms?
Our AI Symptom Checker analyses your symptoms and suggests the most likely diagnoses — including relevant treatment pathways.
Use AI Symptom Checker →